1-6 of 6
Shensi Shen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3268: Biomarkers of drug-tolerant persistent melanoma cells in human, correlation with tumor microenvironment and response to treatment

Hongxu Chen, Shensi Shen, Sara Faouzi, Alexia Alfaro, Dorothee Baille, Séverine Roy, Naima Benannoune, Hugues Hermann, Samad Muhammadnejad, Stephan Vagner, Caroline Robert
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3268.
https://doi.org/10.1158/1538-7445.AM2023-3268
Published: 04 April 2023
View article titled, Abstract 3268: Biomarkers of drug-tolerant persistent melanoma cells in human, correlation with tumor microenvironment and response to treatment
Journal Articles

Abstract 3906: The mRNA translational plasticity of small cell lung carcinoma is associated with its phenotypic transdifferentiation

Haoning Peng, Mengyao Wang, Lu Li, Lunxu Liu, Shensi Shen
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3906.
https://doi.org/10.1158/1538-7445.AM2023-3906
Published: 04 April 2023
View article titled, Abstract 3906: The mRNA translational plasticity of small cell lung carcinoma is associated with its phenotypic transdifferentiation
Journal Articles

The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance

Michaël Cerezo, Caroline Robert, Lunxu Liu, Shensi Shen
Journal: Cancer Research
Cancer Res (2021) 81 (22): 5596–5604.
https://doi.org/10.1158/0008-5472.CAN-21-1466
Published: 15 November 2021
View article titled, The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance
Open the PDF for The Role of mRNA Translational Control in Tumor Immune Escape and Immunotherapy Resistance in another window
Journal Articles

Abstract CT087: Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with BRAF V600E/K-mutant melanoma in the COMBAT trial

Caroline Robert, Shensi Shen, Delphine Allard, Ana Arance Fernández, Caroline Dutriaux, Egbert de Jong, Matthew Squires, Jean-Jacques Grob
Journal: Cancer Research
Cancer Res (2018) 78 (13_Supplement): CT087.
https://doi.org/10.1158/1538-7445.AM2018-CT087
Published: 01 July 2018
View article titled, Abstract CT087: Early tumor immune microenvironment (TME) modulation by the BRAF inhibitor (BRAFi) dabrafenib (D) and/or the MEK inhibitor (MEKi) trametinib (T) in patients (pts) with <em>BRAF</em> V600E/K-mutant melanoma in the COMBAT trial
Journal Articles

Abstract B10: Inhibiting eIF4F-mediated adaptive translatome reprogramming is a salvage strategy for targted melanoma therapy

Shensi Shen, Caroline Robert, Stephan Vagner
Journal: Cancer Research
Cancer Res (2017) 77 (6_Supplement): B10.
https://doi.org/10.1158/1538-7445.Transcontrol16-B10
Published: 14 March 2017
View article titled, Abstract B10: Inhibiting eIF4F-mediated adaptive translatome reprogramming is a salvage strategy for targted melanoma therapy
Journal Articles

17-Hydroxy-jolkinolide B Inhibits Signal Transducers and Activators of Transcription 3 Signaling by Covalently Cross-Linking Janus Kinases and Induces Apoptosis of Human Cancer Cells

Ying Wang, Xiuquan Ma, Shousheng Yan, Shensi Shen, Huiling Zhu, Yuan Gu, Hongbing Wang, Guowei Qin, Qiang Yu
Journal: Cancer Research
Cancer Res (2009) 69 (18): 7302–7310.
https://doi.org/10.1158/0008-5472.CAN-09-0462
Published: 14 September 2009
View article titled, 17-Hydroxy-jolkinolide B Inhibits Signal Transducers and Activators of Transcription 3 Signaling by Covalently Cross-Linking Janus Kinases and Induces Apoptosis of Human Cancer Cells
Open the PDF for 17-Hydroxy-jolkinolide B Inhibits Signal Transducers and Activators of Transcription 3 Signaling by Covalently Cross-Linking Janus Kinases and Induces Apoptosis of Human Cancer Cells in another window
Includes: Supplementary data